 It has a longer elimination half-life than acetazolamide and is less associated with adverse effects to the kidney.Dorzolamide is a sulfonamide and topical carbonic anhydrase II inhibitor.It is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and who are insufficiently responsive to beta-blockers.